NCT05421325View on ClinicalTrials.gov

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

February 28, 2026

Conditions
Immune Deficiency
Interventions
BIOLOGICAL

QBKPN SSI

Site-Specific Immunomodulator

OTHER

Normal Saline Placebo

Normal Saline

Trial Locations (1)

V5G 4X4

RECRUITING

Qu Biologics Trial Site, Burnaby

All Listed Sponsors
collaborator

The National Research Council of Canada Industrial Research Assistance Program

UNKNOWN

lead

Qu Biologics Inc.

INDUSTRY